Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease

Journal of NeuroVirology

Volumn 20, Issue 6, 2014, Pages 591-602

  Meulendyke, Kelly A ^a   Queen, Suzanne E ^a   Engle, Elizabeth L ^a   Shirk, Erin N ^a   Liu, Jiayang ^b   Steiner, Joseph P ^c   Nath, Avindra ^c   Tarwater, Patrick M ^b   Graham, David R ^a   Mankowski, Joseph L ^a   Zink, M Christine ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Paul L Foster School of Medicine   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CNS; Fluconazole; HIV; Paroxetine; Selective serotonin reuptake inhibitor; SIV

Indexed keywords

FLUCONAZOLE; GLYCOPROTEIN GP 120; PAROXETINE; TRANSACTIVATOR PROTEIN; AMYLOID PRECURSOR PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L; NOOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG SCREENING; EMBRYO; FRONTAL CORTEX; HIV ASSOCIATED DEMENTIA; IN VITRO STUDY; IN VIVO STUDY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFILAMENT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; VIRUS REPLICATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; ANIMAL; CEREBROSPINAL FLUID; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; MACACA NEMESTRINA; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIMARY CELL CULTURE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIROLOGY;

MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DISEASE MODELS, ANIMAL; FLUCONAZOLE; GENE EXPRESSION; HUMANS; MACACA NEMESTRINA; NEUROFILAMENT PROTEINS; NEURONS; NOOTROPIC AGENTS; PAROXETINE; PRIMARY CELL CULTURE; RATS; SEROTONIN UPTAKE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84916606478     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-014-0283-1     Document Type: Article

References (60)

1. Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, Rosengren L, Gisslen M (2007) CSF neurofilament protein (NFL)—a marker of active HIV-related neurodegeneration. J Neurol 254:1026–1032. doi:10.1007/s00415-006-0481-8
2. Akay C, Cooper M, Odeleye A, Jensen BK, White MG, Vassoler F, Gannon PJ, Mankowski J, Dorsey JL, Buch AM, Cross SA, Cook DR, Pena MM, Andersen ES, Christofidou-Solomidou M, Lindl KA, Zink MC, Clements J, Pierce RC, Kolson DL, Jordan-Sciutto KL (2014) Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol 20:39–53. doi:10.1007/s13365-013-0227-1
3. Ances BM, Ellis RJ (2007) Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 27:86–92. doi:10.1055/s-2006-956759
4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. doi:10.1212/01.WNL.0000287431.88658.8b
5. Benton T, Lynch K, Dube B, Gettes DR, Tustin NB, Ping Lai J, Metzger DS, Blume J, Douglas SD, Evans DL (2010) Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication. Psychosom Med 72:925–932. doi:10.1097/PSY.0b013e3181f883ce
6. Burudi EM, Marcondes MC, Watry DD, Zandonatti M, Taffe MA, Fox HS (2002). Regulation of indoleamine 2,3-dioxygenase expression in simian immunodeficiency virus-infected monkey brains. J Virol 76: 12233–41. doi:
7. Chiou SH, Chen SJ, Peng CH, Chang YL, Ku HH, Hsu WM, Ho LL, Lee CH (2006) Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 343:391–400. doi:10.1016/j.bbrc.2006.02.180
8. Chung YC, Kim SR, Jin BK (2010) Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson’s disease. J Immunol 185:1230–1237. doi:10.4049/jimmunol.1000208
9. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, Bok E, Jin M, Park ES, Yoon SH, Ko HW, Kim YS, Jin BK (2011) Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 60:963–974. doi:10.1016/j.neuropharm.2011.01.043
10. Clements JE, Babas T, Mankowski JL, Suryanarayana K, Piatak M Jr, Tarwater PM, Lifson JD, Zink MC (2002) The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis 186:905–913. doi:10.1086/343768
11. Clements JE, Mankowski JL, Gama L, Zink MC (2008) The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neurovirol 14:309–317. doi:10.1080/13550280802132832
12. Coultrap SJ, Bayer KU (2012) CaMKII regulation in information processing and storage. Trends Neurosci 35:607–618. doi:10.1016/j.tins.2012.05.003
13. Drewes JL, Meulendyke KA, Liao Z, Witwer KW, Gama L, Ubaida Mohien C, Li M, Notarangelo FM, Tarwater PM, Schwarcz R, Graham DR, Zink MC (submitted). Quinolinic acid/tryptophan ratios are an early predictor of SIV encephalitis in macaques and remain elevated in the brain under cART. doi:
14. Frankland PW, O’Brien C, Ohno M, Kirkwood A, Silva AJ (2001) Alpha-CaMKII-dependent plasticity in the cortex is required for permanent memory. Nature 411:309–313. doi:10.1038/35077089
15. Giometto B, An SF, Groves M, Scaravilli T, Geddes JF, Miller R, Tavolato B, Beckett AA, Scaravilli F (1997) Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities. Ann Neurol 42:34–40. doi:10.1002/ana.410420108
16. Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5:69–81. doi:10.1038/nri1527
17. Gupta RG, Kelly KM, Helke KL, Queen SE, Karper JM, Dorsey JL, Brice AK, Adams RJ, Tarwater PM, Kolson DL, Mankowski JL (2010) HIV and SIV induce alterations in CNS CaMKII expression and activation: a potential mechanism for cognitive impairment. Am J Pathol 176:2776–2784. doi:10.2353/ajpath.2010.090809
18. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, Price RW, Fuchs D (2010) Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 7:15. doi:10.1186/1742-6405-7-15
19. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, Turchan J, Nath A, Mattson MP (2004) Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55:257–267. doi:10.1002/ana.10828
20. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096. doi:10.1212/WNL.0b013e318200d727
21. Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, Vuckevic AJ, Berreira PJ, Cohen BM, Renshaw PF (2000) Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 157:1506–1508. doi:10.1176/appi.ajp.157.9.1506
22. Jessen Krut J, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, Nilsson S, Zetterberg H, Gisslen M (2014) Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One 9:e88591. doi:10.1371/journal.pone.0088591
23. Jiang L, Liu C, Tong J, Mao R, Chen D, Wang H, Huang J, Li L (2014) Fluoxetine pretreatment promotes neuronal survival and maturation after auditory fear conditioning in the rat amygdala. PLoS One 9:e89147. doi:10.1371/journal.pone.0089147
24. Klomp A, Vaclavu L, Meerhoff GF, Reneman L, Lucassen PJ (2014) Effects of chronic fluoxetine treatment on neurogenesis and tryptophan hydroxylase expression in adolescent and adult rats. PLoS One 9:e97603. doi:10.1371/journal.pone.0097603
25. Kristiansen JE, Hansen JB (2000) Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia. Int J Antimicrob Agents 14:209–213. doi:10.1016/S0924-8579(99)00157-0
26. Lee MH, Wang T, Jang MH, Steiner J, Haughey N, Ming GL, Song H, Nath A, Venkatesan A (2011) Rescue of adult hippocampal neurogenesis in a mouse model of HIV neurologic disease. Neurobiol Dis 41:678–687. doi:10.1016/j.nbd.2010.12.002
27. Letendre SL, Marquie-Beck J, Ellis RJ, Woods SP, Best B, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson D, Alexander TJ, Durelle J, Heaton R, Grant I (2007) The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J NeuroImmune Pharmacol 2:120–127. doi:10.1007/s11481-006-9054-y
28. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65–70. doi:10.1001/archneurol.2007.31
29. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK (2009) Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 87:1037–1045. doi:10.1002/jnr.21899
30. Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL (2010) HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J NeuroImmune Pharmacol 5:294–309. doi:10.1007/s11481-010-9205-z
31. Lisman J, Yasuda R, Raghavachari S (2012) Mechanisms of CaMKII action in long-term potentiation. Nat Rev Neurosci 13:169–182. doi:10.1038/nrn3192
32. Maneglier B, Guillemin GJ, Clayette P, Rogez-Kreuz C, Brew BJ, Dormont D, Advenier C, Therond P, Spreux-Varoquaux O (2008) Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT(1A) receptors. Br J Pharmacol 154:174–182. doi:10.1038/bjp.2008.80
33. Mankowski JL, Clements JE, Zink MC (2002a) Searching for clues: tracking the pathogenesis of human immunodeficiency virus central nervous system disease by use of an accelerated, consistent simian immunodeficiency virus macaque model. J Infect Dis 186(Suppl 2):S199–S208. doi:10.1086/344938
34. Mankowski JL, Queen SE, Tarwater PM, Fox KJ, Perry VH (2002b). Accumulation of beta-amyloid precursor protein in axons correlates with CNS expression of SIV gp41. J Neuropathol Exp Neurol 61: 85–90. doi:
35. Mankowski JL, Queen SE, Clements JE, Zink MC (2004) Cerebrospinal fluid markers that predict SIV CNS disease. J Neuroimmunol 157:66–70. doi:10.1016/j.jneuroim.2004.08.031
36. Margolis DM (2014) How might we cure HIV? Curr Infect Dis Rep 16:392. doi:10.1007/s11908-014-0392-2
37. Mattson MP, Maudsley S, Martin B (2004) BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 27:589–594. doi:10.1016/j.tins.2004.08.001
38. Meulendyke KA, Pletnikov MV, Engle EL, Tarwater PM, Graham DR, Zink MC (2012) Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease. J NeuroImmune Pharmacol 7:454–464. doi:10.1007/s11481-011-9332-1
39. Mocchetti I, Bachis A, Campbell LA, Avdoshina V (2014) Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors. J NeuroImmune Pharmacol 9:80–91. doi:10.1007/s11481-013-9488-y
40. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63. doi:10.1016/0022-1759(83)90303-4
41. Nath S, Bachani M, Harshavardhana D, Steiner JP (2012) Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway. J Neurovirol 18:445–455. doi:10.1007/s13365-012-0122-1
42. Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, Brown M, Martin B, Iyun T, Maudsley S, Clark RF, Mattson MP (2007) Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol 205:166–176. doi:10.1016/j.expneurol.2007.01.037
43. Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987:25–31. doi:10.1016/S0006-8993(03)03219-0
44. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington’s disease mouse model. Exp Neurol 210:154–163. doi:10.1016/j.expneurol.2007.10.015
45. Potter MC, Figuera-Losada M, Rojas C, Slusher BS (2013) Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J NeuroImmune Pharmacol 8:594–607. doi:10.1007/s11481-013-9442-z
46. Reynolds GP, Sardar AM (1996). 5-Hydroxytryptamine deficits in the caudate nucleus in AIDS. AIDS 10: 1303–4. doi:
47. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C (1996) Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67:2013–2018. doi:10.1046/j.1471-4159.1996.67052013.x
48. Sardar AM, Reynolds GP (1995) Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci Lett 187:9–12. doi:10.1016/0304-3940(95)11324-P
49. Shibui Y, He XJ, Uchida K, Nakayama H (2009) MPTP-induced neuroblast apoptosis in the subventricular zone is not regulated by dopamine or other monoamine transporters. Neurotoxicology 30:1036–1044. doi:10.1016/j.neuro.2009.07.003
50. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250. doi:10.1097/QAD.0b013e3283354a7b
51. Stagni F, Magistretti J, Guidi S, Ciani E, Mangano C, Calza L, Bartesaghi R (2013) Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of Down syndrome. PLoS One 8:e61689. doi:10.1371/journal.pone.0061689
52. Steiner J, Haughey N, Li W, Venkatesan A, Anderson C, Reid R, Malpica T, Pocernich C, Butterfield DA, Nath A (2006) Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal 8:2089–2100. doi:10.1089/ars.2006.8.2089
53. Thaler F, Bernard B, Tod M, Jedynak CP, Petitjean O, Derome P, Loirat P (1995) Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother 39:1154–1156. doi:10.1128/AAC.39.5.1154
54. Vizi ES, Kisfali M, Lorincz T (2013) Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects. Brain Res Bull 93:32–38. doi:10.1016/j.brainresbull.2012.10.005
55. Weed MR, Hienz RD, Brady JV, Adams RJ, Mankowski JL, Clements JE, Zink MC (2003) Central nervous system correlates of behavioral deficits following simian immunodeficiency virus infection. J Neurovirol 9:452–464. doi:10.1080/13550280390218751
56. Xing S, Siliciano RF (2013) Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 18:541–551. doi:10.1016/j.drudis.2012.12.008
57. Zhang F, Zhou H, Wilson BC, Shi JS, Hong JS, Gao HM (2012) Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 18(Suppl 1):S213–S217. doi:10.1016/S1353-8020(11)70066-9
58. Zink MC, Suryanarayana K, Mankowski JL, Shen A, Piatak M, Jr., Spelman JP, Carter DL, Adams RJ, Lifson JD, Clements JE (1999). High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 73: 10480–8. doi:
59. Zink MC, Coleman GD, Mankowski JL, Adams RJ, Tarwater PM, Fox K, Clements JE (2001) Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J Infect Dis 184:1015–1021. doi:10.1086/323478
60. Zink MC, Brice AK, Kelly KM, Queen SE, Gama L, Li M, Adams RJ, Bartizal C, Varrone J, Rabi SA, Graham DR, Tarwater PM, Mankowski JL, Clements JE (2010) Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 202:161–170. doi:10.1086/653213